MYGN - ミリアド・ジェネティックス (Myriad Genetics Inc.)

MYGNのニュース

   Investing in Myriad Genetics Inc. (MYGN) might be a great opportunity, but the stock is a bit overvalued  2022/11/30 12:08:00 US Post News
Myriad Genetics Inc. (NASDAQ:MYGN) closed Tuesday at $19.17 per share, up from $18.85 a day earlier. While Myriad Genetics Inc. has overperformed by 1.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -29.13%, with highs and lows ranging from $28.45 to $15.38, whereas […]
   Investing in Myriad Genetics Inc. (MYGN) might be an excellent idea, but the stock is currently overvalued/undervalued  2022/11/17 16:00:00 US Post News
Myriad Genetics Inc. (NASDAQ:MYGN) marked $19.96 per share on Wednesday, down from a previous closing price of $20.88. While Myriad Genetics Inc. has underperformed by -4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -33.20%, with highs and lows ranging from $30.29 to […]
   Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting  2022/11/14 13:00:00 GlobeNewswire
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41 st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.
   Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information  2022/11/10 13:00:00 GlobeNewswire
SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.
   Why Shares of Myriad Genetics Dropped 24% This Week  2022/11/04 01:51:00 The Motley Fool
The genetic-testing company announced an acquisition and lowered its guidance.
   Myriad Genetics, Inc. (MYGN) Q3 2022 - Earnings Call Transcript  2022/11/02 01:41:06 Seeking Alpha
Myriad Genetics, Inc. (NASDAQ:NASDAQ:MYGN) Q3 2022 Earnings Conference Call November 01, 2022, 04:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO,…
   Myriad Genetics, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:MYGN)  2022/11/02 01:40:54 Seeking Alpha
The following slide deck was published by Myriad Genetics, Inc.
   Myriad Genetics falls 19% after lowering full-year guidance, Q3 misses (NASDAQ:MYGN)  2022/11/01 15:52:16 Seeking Alpha
Myriad Genetics (MYGN) is down 19% in Tuesday morning trading after it narrowed its 2022 full-year guidance and its Q3 2022 financial results missed on the top and bottom lines.
   Myriad Genetics Acquires Gateway Genomics as Q3 Revenues Drop 7 Percent, Miss Estimates  2022/11/01 14:51:05 GenomeWeb
The company reported $156.4 million in Q3 revenues compared to $167.3 million last year, and acquired consumer genetics firm Gateway Genomics.
   Myriad Genetics Slashes FY22 Outlook As Q3 Results Miss Estimates; Stock Down 8%  2022/11/01 14:15:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Tuesday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings and revenue …
   Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member  2022/10/31 20:30:00 GlobeNewswire
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its Board of Directors, effective immediately.
   Myriad Genetics Q3 2022 Earnings Preview  2022/10/31 16:14:45 Seeking Alpha
Myriad Genetics (MYGN) is scheduled to announce Q3 earnings results on Tuesday, November 1st, before market open.The consensus EPS Estimate is -$0.08 (-300.0% Y/Y) and the consensus…
   Earnings Preview: Myriad Genetics  2022/10/31 14:24:34 Benzinga
Myriad Genetics (NASDAQ: MYGN ) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here''s what investors need to know before the announcement. Analysts estimate that Myriad Genetics will report an earnings per share (EPS) of $-0.06. Myriad Genetics bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
   The Myriad Genetics Inc. (MYGN) had a good session last reading, didn’t it?  2022/10/28 11:32:00 US Post News
In Thursday’s session, Myriad Genetics Inc. (NASDAQ:MYGN) marked $20.20 per share, up from $20.06 in the previous session. While Myriad Genetics Inc. has overperformed by 0.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -34.07%, with highs and lows ranging from $32.35 to […]
   Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022  2022/10/26 20:05:00 GlobeNewswire
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov. 1, 2022 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day prior to the market opening.

calendar